Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.68 |
| ▸ | TSHR | P16473 | 3/20 | 0.68 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 3/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6031412 | 0.98 | GAA (0.68) | HTTTSHRCHEK1KMT2AGAA | |
| SCHEMBL914395 | 0.97 | NPSR1 (0.68) | HTTTSHRCHEK1KMT2AGAA | |
| SCHEMBL736600 | 0.81 | HTT (1.00) | HTTTSHRCHEK1KMT2AGAA | |
| SCHEMBL914710 | 0.79 | GAA (1.00) | HTTTSHRCHEK1KMT2AGAA | |
| SCHEMBL916128 | 0.77 | NPSR1 (1.00) | HTTTSHRCHEK1KMT2AGAA | |
| SCHEMBL913457 | 0.71 | LIMK1 (0.50) | HTTTSHRCHEK1KMT2AGAA | |
| SCHEMBL16724451 | 0.70 | LIMK1 (0.53) | HTTTSHRCHEK1KMT2AGAA | |
| SCHEMBL914020 | 0.70 | LIMK1 (0.51) | HTTTSHRCHEK1KMT2AGAA | |
| SCHEMBL914350 | 0.68 | LIMK1 (0.50) | HTTTSHRCHEK1KMT2AGAA | |
| SCHEMBL735589 | 0.67 | LIMK1 (0.66) | HTTTSHRGAAALDH1A1LIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872052-B2 | Use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | QUANTUM LTO HOLDINGS, LLC | 2006-11-16 | — | — | US | disclosed |
| EP-1631295-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | Arexis AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004108139-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | AREXIS AB (SE) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | RCE1, CTSE, SPINT2 | HTT 3172/4885TSHR 4590/4885CHEK1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.